From short-acting to long-acting formulations, the wide range of GLP- 1 receptor agonists available provides physicians with numerous options to tailor treatment to each patient's needs
Loos, a professor at the University of Copenhagen and affiliated with a research center supported by the Novo Nordisk Foundation (the maker of Wegovy and Ozempic), noted, "The current model explains only 25% of the variability, and further research is needed to uncover the remaining 75%." However, she also expressed optimism, stating, "By combining genetic and clinical information, the era of personalized medicine, where we can select the best drug for each patient, may be upon us."
Genetics: Some individuals are genetically predisposed to have skin with lower elasticity , making them more prone to sagging
Identifying the cause prevents recurrence with future vials
Muscle loss can slow your metabolism, increase fatigue, and even raise your risk of regaining weight